SCHEMBL479407

SCHEMBL479407

CN(c1cccc(C(=O)N(N)NS(C)(=O)=O)c1)c1cnc2nc(N)nc(N)c2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 12/20 0.39
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA9 Q16790 1/20 0.37
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
PIK3CG P48736 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HDAC4 P56524 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC9 Q9UKV0 1/20 0.35
HDAC5 Q9UQL6 1/20 0.35
KDM4E B2RXH2 1/20 0.35
TLR4 O00206 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
TYMS P04818 1/20 0.35
GLA P06280 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL479180 0.83 DHFR (0.48) DHFRPIK3CAPIK3CBPIK3CGHDAC6
SCHEMBL479348 0.74 DHFR (0.45) DHFRPIK3CAPIK3CBPIK3CGHDAC6
SCHEMBL13584032 0.72 DHFR (0.43) DHFRPIK3CAPIK3CBPIK3CGHDAC6
SCHEMBL13583145 0.71 CA1 (0.55) DHFRCA1CA2CA9PIK3CG
Water SCHEMBL9320891 0.71 DHFR (0.49) DHFRHDAC4HDAC7HDAC9HDAC5
SCHEMBL480956 0.70 PIK3CG (0.42) DHFRPIK3CAPIK3CBPIK3CGHDAC6
SCHEMBL11633098 0.70 DHFR (0.43) DHFRCA1CA2CA9HDAC4
SCHEMBL479157 0.68 DHFR (0.45) DHFRCA1CA2CA9KDM4E
SCHEMBL479287 0.67 HDAC4 (0.48) DHFRCA1CA2CA9PIK3CG
SCHEMBL479193 0.67 DHFR (0.45) DHFRKDM4ETLR4MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120283219-A1 DIAMINOPTERIDINE DERIVATIVES BIORELIX, INC. 2012-11-08 US disclosed
EP-2410856-A1 DIAMINOPTERIDINE DERIVATIVES Biorelix, Inc. (US) 2012-02-01 EP disclosed
WO-2010110907-A1 DIAMINOPTERIDINE DERIVATIVES BIORELIX, INC. (US) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283219-A1 DIAMINOPTERIDINE DERIVATIVES MPO, AOC1, DCTD DHFR 19/4885CA1 4547/4885CA2 3602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.